You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 4, 2024

Details for New Drug Application (NDA): 216436


✉ Email this page to a colleague

« Back to Dashboard


NDA 216436 describes ATORVASTATIN CALCIUM, which is a drug marketed by Accord Hlthcare, Agnitio, Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Ltd, Biocon Pharma, Cadila Pharms Ltd, Dr Reddys, Dr Reddys Labs Ltd, Graviti Pharms, Hetero Labs Ltd V, Invagen Pharms, Lannett Co Inc, Laurus, Lepu Pharm, Lupin Ltd, Macleods Pharms Ltd, Mankind Pharma, Micro Labs Ltd India, MSN, Mylan Pharms Inc, Perrigo R And D, Sandoz Inc, Sciegen Pharms Inc, Shandong Xinhua, Strides Pharma, Sun Pharm Inds Ltd, Teva Pharms, Teva Pharms Usa, Umedica, and Zydus Pharms, and is included in thirty-two NDAs. It is available from sixty-four suppliers. Additional details are available on the ATORVASTATIN CALCIUM profile page.

The generic ingredient in ATORVASTATIN CALCIUM is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
Summary for 216436
Tradename:ATORVASTATIN CALCIUM
Applicant:Biocon Pharma
Ingredient:atorvastatin calcium
Patents:0
Pharmacology for NDA: 216436
Medical Subject Heading (MeSH) Categories for 216436
Suppliers and Packaging for NDA: 216436
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATORVASTATIN CALCIUM atorvastatin calcium TABLET;ORAL 216436 ANDA A-S Medication Solutions 50090-6890 50090-6890-0 30 TABLET, FILM COATED in 1 BOTTLE (50090-6890-0)
ATORVASTATIN CALCIUM atorvastatin calcium TABLET;ORAL 216436 ANDA A-S Medication Solutions 50090-6890 50090-6890-1 90 TABLET, FILM COATED in 1 BOTTLE (50090-6890-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Nov 23, 2022TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Nov 23, 2022TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG BASE
Approval Date:Nov 23, 2022TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.